

# NIEUWSBRIEF KLINISCHE STUDIES THORAXONCOLOGIE

APRIL 2025

<https://www.unicra.be/lung-cancer-trials/>



## NIEUWE STUDIES IN DE KIJKER

**MK-2870-019 (Merck):** A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

*stage II-IIIb NSCLC perioperatief – inclusie na resectie mogelijk*

## NIET-KLEINCELLIG LONGCARCINOOM

**PACIFIC-8 (AstraZeneca):** A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab in Participants with Locally Advanced (Stage III), Unresectable NSCLC Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy

*stage III NSCLC – na concurrente chemoradiotherapie*

**LUNG Platform (GSK):** A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, PD-L1-Selected NSCLC

*NSCLC 1L – PD-L1 $\geq$ 50%*

**KRYSTAL-7 (Mirati Therapeutics):** A Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation.

*NSCLC 1L – non-squamous – KRAS G12C + PD-L1 $\geq$ 50%*

**SAFFRON (AstraZeneca):** A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Vs Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic NSCLC Who Have Progressed on Treatment With Osimertinib

*NSCLC – EGFR $m^+$  na osimertinib*

Voor meer informatie contacteer **Giete Moons**

Stafleden thoraxoncologie: **Annelies Janssens** | **Jo Raskin** | **Reinier Wener** | **Mick van de Wiel**

Fase I studies: **Bernd Dekeyser**

**TeliMET NSCLC-01 (AbbVie):** A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous NSCLC

*NSCLC 2L – non-squamous cMET overexp – nog geen docetaxel gehad*

**WU-KONG28 (Dizal):** A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

*NSCLC 1L – EGFR exon 20 insertion*

**KRASCENDO-1 (Roche):** A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Divarasis Versus Sotorasib Or Adagrasib In Patients With Previously Treated KRAS G12C-Positive Advanced Or Metastatic Non-Small Cell Lung Cancer

*NSCLC 2-4L – KRAS G12C*

**MK-2870-019 (Merck):** A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIb (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

*stage II-IIIb NSCLC perioperatief – inclusie na resectie mogelijk*

**INTerpath-002 (Merck):** A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIb (N2) Non-small Cell Lung Cancer

*stage II-IIIb NSCLC 1L – R0 resected*

**DO2.22.01 (Deuter Oncology):** A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours

*NSCLC post SOC – METamp/METex14skipping*

**21820 (Bayer):** First-in-human dose-escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of the anti-CCR8 antibody BAY 3375968 as monotherapy and in combination with pembrolizumab in participants with selected advanced solid tumors

*NSCLC post SOC*

Momenteel sloten beschikbaar

Voor meer informatie contacteer **Giete Moons**

Stafleden thoraxoncologie: **Annelies Janssens** | **Jo Raskin** | **Reinier Wener** | **Mick van de Wiel**

Fase I studies: **Bernd Dekeyser**

**20210023 (AMGEN):** AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

*NSCLC post SOC - squamous - MTAP-verlies*

**IMC-F106C-101 (Immunocore):** A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A\*02:01-Positive Participants with Advanced PRAME-Positive Cancers

*NSCLC post SOC - HLA-A\*02:01-positief en PRAME-positief*

**20210104 (AMGEN):** A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression

*NSCLC adeno 2L - FGFR2b overexp*

*On hold*

**21948 (Bayer):** An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase zeta inhibitor (DGKzi) BAY 2965501 as monotherapy, and in combination, in participants with advanced solid tumors

*NSCLC prior SOC*

*Momenteel geen sloten*

**DAREON-7 (Boehringer):** A Phase I, open-label, dose escalation and expansion trial to investigate safety and tolerability of BI 764532 intravenous infusions in combination with standard of care (platinum and etoposide) in first-line treatment of patients with neuroendocrine carcinomas

*LCNEC 1L - DLL3+*

**CDR404-001 (CDR-Life AG):** A Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A\*02:01 Participants With MAGE-A4 Expressing Solid Tumors

*NSCLC post SOC - HLA-A\*02:01-positief en MAGE-A4-positief*

Voor meer informatie contacteer [Giete Moons](#)

Stafleden thoraxoncologie: [Annelies Janssens](#) | [Jo Raskin](#) | [Reinier Wener](#) | [Mick van de Wiel](#)

Fase I studies: [Bernd Dekeyser](#)

**JK06.1.01 (Salubris):** A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients With Unresectable Locally Advanced or Metastatic Cancer

*NSCLC post SOC*

*Wachttijst*

**GO43860 (Genentech):** A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

*NSCLC post SOC*

*Momenteel sloten voor 10 naïeve patiënten*

## **KLEINCELLIG LONGCARCINOOM**

**PRIMALung (EORTC):** PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients

*LD-SCLC en ED-SCLC na (immuno)chemotherapie of chemoradiotherapie*

## **PLEURAAL MESOTHELIOOM**

**HiPeRMESO (Academisch):** High-intensity Pleural Radiotherapy after (extended) pleurectomy and decortication in patient with pleural MESOthelioma

*adjuvant mesotheliom 1L*

## **SOLIDE TUMOREN – PSYCHOSOCIAAL**

**REMOTE (Academisch)** Targeting Fear of Cancer Recurrence in Cancer Survivors: a multicentre randomized controlled trial to evaluate Internet-Based Emotional Freedom Techniques and Internet-Based Mindfulness Meditation as intervention strategies

*Kankerpatiënten in remissie met angst voor herval*

Voor meer informatie contacteer **Giete Moons**

Stafleden thoraxoncologie: **Annelies Janssens** | **Jo Raskin** | **Reinier Wener** | **Mick van de Wiel**

Fase I studies: **Bernd Dekeyser**

## EPITHELIALE TUMOREN VAN DE THYMUS

Geen beschikbare studies

## OVERZICHT VAN ALLE LOPENDE STUDIES IN BELGIË



Voor meer informatie contacteer **Giete Moons**

Stafleden thoraxoncologie: **Annelies Janssens** | **Jo Raskin** | **Reinier Wener** | **Mick van de Wiel**

Fase I studies: **Bernd Dekeyser**